Abstract

The article discusses fundamental issues concerning the procedure of monitoring adverse effects of medicinal products in the context of personal data protection regulations. The article pays special attention to the differentiation of channels for providing patient information to entities responsible for indirect and direct channels. It analyses legal grounds, the extent and purpose of data processing, as well as the issues connected with the implementation of the obligation to inform. It also discusses the basis for the qualification of information collected under this procedure as personal data.